Muscle preservation during GLP-1 therapy

Weight loss at speed can come with a trade-off. The published literature on lean mass during GLP-1 therapy is worth understanding before you start.

TL;DR

• Lean mass loss is a well-documented concern during any rapid weight reduction, including GLP-1-assisted weight loss — it’s not unique to this therapy, but it is relevant.
• Published sub-analyses from the STEP trials and related research suggest resistance training and adequate protein intake are associated with better lean mass retention outcomes.
• This is an active area of research; the evidence base is growing but not yet definitive for all populations.

What it is

When body weight decreases rapidly, not all of the lost mass is fat. Skeletal muscle can account for a meaningful portion of the total weight reduction, particularly when caloric intake drops significantly or physical activity is insufficient. This phenomenon — sometimes called “anabolic insufficiency during weight loss” in the clinical literature — is not specific to GLP-1 therapies. It has been described in research on caloric restriction, bariatric surgery outcomes, and other weight-management interventions. The question researchers and clinicians are actively examining is whether the appetite-suppressing effects of GLP-1 receptor agonists — which can substantially reduce caloric intake — make this trade-off more pronounced.

How it works

GLP-1 receptor agonists reduce appetite centrally and slow gastric emptying, which tends to result in lower total caloric intake. If protein intake falls significantly alongside total calories, the body has less raw material available for muscle protein synthesis. Simultaneously, without an anabolic stimulus — primarily resistance exercise — the signal to preserve skeletal muscle is reduced. The combination of reduced protein availability and reduced mechanical load is well-described in the exercise physiology literature as a driver of lean mass loss during caloric restriction.

Who asks about it

People come to this topic when they have heard about muscle loss in the context of GLP-1 therapy and want to understand whether it’s something they should be actively managing. The concern is particularly common among people who have invested years in building functional strength or physical capacity and don’t want to lose it during a weight-management phase. It’s also a question that arises in the context of older adults, where lean mass is more tightly linked to mobility, independence, and metabolic health.

What the research says

A sub-analysis of the STEP 1 trial data, examining body composition changes via DEXA scan, reported that a portion of total weight lost was lean mass — a finding consistent with weight loss interventions more broadly. Villareal et al. in JAMA Internal Medicine (2017) examined exercise modalities during weight loss in older adults and found that resistance training combined with weight loss preserved lean mass and functional capacity better than either aerobic exercise or weight loss alone. More recently, researchers have begun examining whether adjunct approaches — including adequate dietary protein targets of 1.2–1.6 g/kg of body weight, as described in the European Society for Clinical Nutrition guidelines — can further attenuate lean mass loss during GLP-1-assisted weight reduction. The data here is preliminary and the field is evolving.

What to know before considering it

GLP-1 therapy requires a licensed clinician evaluation and valid prescription. Any individual considering GLP-1-based weight management should discuss body composition monitoring, protein intake targets, and exercise programming with their clinician. Resistance training and adequate protein intake are the two most consistently cited behavioral factors in the lean mass preservation literature. Compounded GLP-1 formulations are prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved.

The Halftime POV

This is one of the more important clinical conversations to have before starting GLP-1 therapy, not after. The goal of weight management in the second half of life isn’t just a number on a scale — it’s maintaining the body composition that supports long-term function. Knowing what the literature says about lean mass before you start puts you in a better position to manage the outcome intentionally.

Related reading:

• Glp1 Mechanism Basics
• Glp1 Rebound Weight
• Dexa Body Composition

FAQ

Q: Does GLP-1 therapy cause muscle loss? A: Published literature documents lean mass loss alongside fat mass loss during GLP-1 therapy — the proportion varies by study. The STEP trial series showed total weight loss consisting of roughly 10–40% lean mass depending on the study population and protocol. This is a clinical concern because muscle loss has independent metabolic and functional consequences.

Q: How can lean mass be preserved during GLP-1 therapy? A: Published literature points to adequate protein intake (1.2–1.6g per kg body weight is a commonly cited target) and resistance training as the primary strategies supported by evidence. Some clinicians combine GLP-1 therapy with GH-axis peptides in protocols designed to counteract lean mass loss — this is an area of active clinical interest but limited trial data.

Q: What tests can track body composition during GLP-1 therapy? A: DEXA (dual-energy X-ray absorptiometry) is the most precise available tool for tracking lean mass, fat mass, and bone density separately. It is more informative than scale weight alone. Clinicians using DEXA before and during GLP-1 protocols can distinguish fat loss from lean mass changes and adjust protocols accordingly.

Disclaimer

This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.

Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021 (STEP 1 — body composition sub-analysis)
• Villareal DT, et al. “Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults.” NEJM, 2017
• Villareal DT, et al. “Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults.” NEJM, 2011
• Cederholm T, et al. “ESPEN guidelines on definitions and terminology of clinical nutrition.” Clinical Nutrition, 2017